Literature DB >> 9685942

Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.

M Muraoka1, Z Hu, T Shimokawa, S Sekino, R Kurogoshi, Y Kuboi, Y Yoshikawa, K Takada.   

Abstract

The delivery ability of a pressure-controlled colon delivery capsule (PCDC) containing caffeine as a test drug was evaluated after oral administration to healthy male human volunteers. The driving force causing PCDC disintegration in the intestinal tract is the physiological luminal pressure which results from peristalsis. Three kinds of PCDCs having different thickness of a water-insoluble polymer membrane was prepared by coating the inner surface of the gelatin capsules with ethylcellulose (EC). The mean thickness were 40 +/- 1 (SE) for type 1, 44 +/- 1 for type 2 and 50 +/- 1 micron for type 3 PCDC, respectively. Caffeine was dissolved with a suppository base (PEGs 400 and 1000) and the capsules were filled. Doses were 15, 45 or 75 mg. After blank saliva samples were obtained, test preparations were orally administered to the volunteers and saliva samples were collected for 1 min intervals hourly from 1 to 10 h in the fasted state study, and from 1 to 20 h and at 25 h in the fed state study. Caffeine concentrations in the saliva samples were analyzed by HPLC. The maximum salivary caffeine excretion rate increased as the oral caffeine dose increased. The maximum salivary caffeine excretion rate increased predominantly compared to the pre-dose level in 75 mg dose study. Therefore, all following studies were performed with this dose. The first appearance time of caffeine into the saliva, TI, was used as a parameter to estimate the disintegration time of test preparations in the gastrointestinal tract. The mean TI of types 1, 2, and 3 PCDCs were 3.0 +/- 0.4, 4.0 +/- 0.4 and 4.5 +/- 0.3 h, respectively. After oral administration of 75 mg caffeine in pain gelatin capsule as a reference preparation, caffeine appeared in the saliva within 0.5 h. The mean hardness of the PCDCs were 1.05 +/- 0.10 (type 1), 1.55 +/- 0.06 (type 2) and 2.08 +/- 0.15 newton (type 3), respectively. There were good correlations between three parameters: EC coating membrane thickness, hardness and TI (determination coefficient r2 = 0.935 between TI and thickness, r2 = 0.998 between thickness and hardness, r2 = 0.958 between hardness and TI). The effect of food intake on the delivery ability was examined with type 3 PCDCs. Food intake prolonged the mean TI, from 4.5 +/- 0.3 to 7.8 +/- 1.3 h. This increase is thought to be ascribed to prolonged gastric emptying time. Comparison with reported colon arrival times indicates that the type 3 PCDC functions in colon delivery of caffeine and is thought to be applicable to other drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685942     DOI: 10.1016/s0168-3659(97)00201-0

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  11 in total

1.  Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects.

Authors:  Z Hu; S Mawatari; N Shibata; K Takada; H Yoshikawa; A Arakawa; Y Yosida
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 2.  ["Targeted delivery" in the gastrointestinal tract].

Authors:  C S Leopold
Journal:  Med Klin (Munich)       Date:  1999-02-15

3.  Colon targeted drug delivery systems: a review on primary and novel approaches.

Authors:  Anil K Philip; Betty Philip
Journal:  Oman Med J       Date:  2010-04

4.  Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting.

Authors:  Yi-Nuo Pang; Yan Zhang; Zhi-Rong Zhang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

5.  Acid-Labile Polyvinylamine Micro- and Nanogel Capsules.

Authors:  Lianjun Shi; Cory Berkland
Journal:  Macromolecules       Date:  2007       Impact factor: 5.985

6.  Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells.

Authors:  In-Ah Lee; Daren Low; Alan Kamba; Victoria Llado; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2013-08-08       Impact factor: 7.527

7.  Development of a chitosan based double layer-coated tablet as a platform for colon-specific drug delivery.

Authors:  Min Soo Kim; Dong Woo Yeom; Sung Rae Kim; Ho Yub Yoon; Chang Hyun Kim; Ho Yong Son; Jin Han Kim; Sangkil Lee; Young Wook Choi
Journal:  Drug Des Devel Ther       Date:  2016-12-21       Impact factor: 4.162

8.  Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects.

Authors:  Supanimit Teekachunhatean; Nisanuch Tosri; Noppamas Rojanasthien; Somdet Srichairatanakool; Chaichan Sangdee
Journal:  ISRN Pharmacol       Date:  2013-03-04

9.  Design, development, and optimization of polymeric based-colonic drug delivery system of naproxen.

Authors:  Pooja Sharma; Anuj Chawla; Pravin Pawar
Journal:  ScientificWorldJournal       Date:  2013-10-01

Review 10.  Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy.

Authors:  Congcong Lin; Huei Leng Helena Ng; Weisan Pan; Hubiao Chen; Ge Zhang; Zhaoxiang Bian; Aiping Lu; Zhijun Yang
Journal:  Int J Mol Sci       Date:  2015-11-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.